AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.
about
Pharmacological treatment options for mast cell activation diseaseThe novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoAR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB.c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies.Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.A novel class of small molecule inhibitors of HDAC6.Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinomaOverexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis.Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideEfficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.SIAH proteins: critical roles in leukemogenesis.Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.Epigenetic drugs for cancer treatment and prevention: mechanisms of action.The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells.CD72 negatively regulates mouse mast cell functions and down-regulates the expression of KIT and FcεRIα.Inactivation of HDAC3 and STAT3 is critically involved in 1-stearoyl-sn-glycero-3-phosphocholine-induced apoptosis in chronic myelogenous leukemia K562 cells.The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γIn vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor.Pim1 kinase regulates c-Kit gene translation.Targeted Treatment Options in Mastocytosis.Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma
P2860
Q26748784-FB65D508-FA80-40C3-B70C-1C5AD889E459Q28751751-234FEDD3-642D-49A6-88BB-A671812F116CQ30464276-DA84EBB2-5E95-4373-9980-79254883A6ABQ33597695-1ACF3E9A-B1BD-43D5-95ED-E708BCE7A65AQ33677797-76306732-05EB-4A49-8644-DAC4C5CBEC50Q33934617-5685DC52-2C70-4CDF-84E4-8D8A3DE81620Q34065056-D2E5A050-2541-44C7-8321-989CBBBD180AQ34282488-1BCC023C-469D-485F-B00D-D8E9EB1331C6Q35092066-0B823F38-9F24-4AC8-AE43-77F4971C6F73Q35206543-63185177-5FC7-41B0-8F34-43AE3456FEABQ36159870-A9B4BFF0-8C8D-4769-95C1-94F609708216Q36256343-B00B790B-C226-4359-8F34-8A56602BA262Q36544516-FC63AF32-0FB6-4189-8B3E-CEF5D9BB2A29Q36758025-D482CE28-0881-44AD-BAC6-342520F22E4CQ37222637-57254D91-4971-4C25-B2B6-FE0AC360FAA4Q37447349-53C1C645-1766-4A14-BA84-BBF613DD9B5BQ37589250-C76BB1DD-F02C-4A50-8180-B27D48B99EF8Q37706037-A2BADB25-D723-4439-8153-C68FC55ACAF5Q38049544-4D10CBE2-4C6A-4849-BAA4-B09C8E386D23Q38155850-AFD4D8C3-DA0E-47AF-86D2-D908A87747AAQ38177821-3DF4BD64-BD5A-4EE4-8FA7-5C0E5F8B41ADQ38472433-95282514-9CB4-41D3-BCA7-0909CB49626EQ38717140-7EAA926F-6AEF-4FCF-8E1D-78DC59BE100AQ38795594-22FDB5B2-087E-4618-B71B-D98D75AF9A6DQ38954933-A3C3FF1E-9FCC-4E16-BD61-8B00E76E5113Q39144692-2CFAB77B-F462-4121-9B83-E184F72710C0Q39339685-A95BF72F-657E-43F0-A582-6EA5BFEEE5DDQ39562665-2F4309B5-BDAF-4100-9DC7-78434A0B1CBEQ40348073-5FC7CA7D-6E77-444A-8EC3-4D56985EF8A7Q41061871-46641A95-5DC0-4262-81AA-7894D20C1704Q41769694-F1E08DCF-E561-497C-89AF-20DAB3BC0F99Q47224057-35374AE0-15B6-4072-9E28-4F7511ADD540Q52691397-89C9381B-93A3-4B92-B1CA-0520F6AF5D98Q54626445-6C747A4C-762A-49E2-BDB6-386B991670B1Q57787094-A6A28287-FD6E-4684-8FBF-413642D295CA
P2860
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@en
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@nl
type
label
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@en
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@nl
prefLabel
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@en
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@nl
P2093
P2860
P1433
P1476
AR-42, a novel HDAC inhibitor, ...... constitutively activated Kit.
@en
P2093
Cheryl A London
Ching-Shih Chen
Dasheng Wang
Joelle Fenger
Misty D Bear
Samuel K Kulp
Sridhar Murahari
Tzu-Yin Lin
William C Kisseberth
P2860
P304
P356
10.1182/BLOOD-2009-07-231985
P407
P577
2010-03-16T00:00:00Z